BAL
MCID: ACT216
MIFTS: 35

Acute Leukemia of Ambiguous Lineage (BAL)

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

MalaCards integrated aliases for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 53 6 38
Mixed Phenotype Acute Leukemia 53 72
Acute Biphenotypic Leukemia 53 72
Acute Leukemia of Indeterminate Lineage 53
Acute Leukemia of Undetermined Lineage 53
Undifferentiated Acute Leukemia 53
Acute Undifferentiated Leukemia 72
Mixed Lineage Acute Leukemia 53
Biphenotypic Acute Leukaemia 29
Biphenotypic Acute Leukemia 53
Aml with Lymphoid Markers 53
All with Myeloid Markers 53
Hybrid Acute Leukemia 53
Bal 53

Classifications:



External Ids:

UMLS 72 C0023464 C0280141 C2826025

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as mixed phenotype acute leukemia, is related to leukemia, acute myeloid and idiopathic acute eosinophilic pneumonia. An important gene associated with Acute Leukemia of Ambiguous Lineage is VHL (Von Hippel-Lindau Tumor Suppressor). The drugs Cytarabine and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and t cells.

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 253, show less)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 12.0
2 idiopathic acute eosinophilic pneumonia 11.3
3 sarcoidosis 1 10.7
4 lung disease 10.7
5 acute leukemia 10.7
6 idiopathic interstitial pneumonia 10.6
7 pulmonary fibrosis 10.6
8 pulmonary fibrosis, idiopathic 10.5
9 leukemia 10.5
10 dermatitis 10.5
11 pulmonary sarcoidosis 10.5
12 extrinsic allergic alveolitis 10.5
13 mercury poisoning 10.5
14 bronchiolitis 10.4
15 pneumonia 10.4
16 wilson disease 10.4
17 bronchiolitis obliterans 10.4
18 interstitial lung disease 10.4
19 cytokine deficiency 10.4
20 lymphocytic leukemia 10.3
21 myeloid leukemia 10.3
22 bronchitis 10.3
23 balo concentric sclerosis 10.3
24 leukemia, acute lymphoblastic 10.3
25 hematopoietic stem cell transplantation 10.3
26 essential thrombocythemia 10.3
27 asbestosis 10.3
28 allergic hypersensitivity disease 10.3
29 pulmonary tuberculosis 10.3
30 encephalopathy 10.3
31 asbestos intoxication 10.3
32 fibrosis of extraocular muscles, congenital, 1 10.2
33 cryptogenic organizing pneumonia 10.2
34 respiratory failure 10.2
35 eosinophilic pneumonia 10.2
36 cystic fibrosis 10.2
37 invasive aspergillosis 10.2
38 vascular disease 10.2
39 encephalitis 10.2
40 hypereosinophilic syndrome 10.2
41 graft-versus-host disease 10.2
42 leukemia, acute lymphoblastic 3 10.2
43 precursor t-cell acute lymphoblastic leukemia 10.2
44 leukemia, chronic myeloid 10.2
45 acute promyelocytic leukemia 10.2
46 lymphoblastic lymphoma 10.2
47 asthma 10.2
48 porphyria 10.2
49 bacterial pneumonia 10.2
50 proteasome-associated autoinflammatory syndrome 1 10.1
51 pulmonary disease, chronic obstructive 10.1
52 pneumoconiosis 10.1
53 silicosis 10.1
54 anthracosis 10.1
55 allergic asthma 10.1
56 acute respiratory distress syndrome 10.1
57 langerhans cell histiocytosis 10.1
58 hydrops, lactic acidosis, and sideroblastic anemia 10.1
59 pneumocystosis 10.1
60 pulmonary edema 10.1
61 neutropenia 10.1
62 farmer's lung 10.1
63 purpura 10.1
64 histiocytosis 10.1
65 influenza 10.1
66 chronic eosinophilic pneumonia 10.1
67 bronchiectasis 10.1
68 heavy metal poisoning 10.1
69 pancytopenia 10.0
70 acute graft versus host disease 10.0
71 chromosomal triplication 10.0
72 tetraploidy 10.0
73 myelofibrosis 10.0
74 polycythemia vera 10.0
75 aspergillosis 10.0
76 myelodysplastic syndrome 10.0
77 myeloma, multiple 10.0
78 down syndrome 10.0
79 leukemia, chronic lymphocytic 10.0
80 patau syndrome 10.0
81 visual epilepsy 10.0
82 candidiasis 10.0
83 thrombocytopenia 10.0
84 myeloproliferative neoplasm 10.0
85 hematologic cancer 10.0
86 pyoderma 10.0
87 acute t cell leukemia 10.0
88 monoclonal gammopathy of uncertain significance 10.0
89 childhood leukemia 10.0
90 arthritis 10.0
91 pyoderma gangrenosum 10.0
92 myeloid sarcoma 10.0
93 exophthalmos 10.0
94 b- and t-cell mixed leukemia 10.0
95 47,xyy 10.0
96 leukemia, b-cell, chronic 10.0
97 splenomegaly 10.0
98 tetrasomy 21 10.0
99 seizure disorder 10.0
100 interstitial pneumonitis, desquamative, familial 10.0
101 lung cancer 10.0
102 pulmonary alveolar proteinosis 10.0
103 pneumothorax 10.0
104 hepatitis 10.0
105 nonspecific interstitial pneumonia 10.0
106 syphilis 10.0
107 neuropathy 10.0
108 pulmonary emphysema 10.0
109 alopecia 10.0
110 beryllium disease 10.0
111 granulocytopenia 10.0
112 chronic beryllium disease 10.0
113 branchiootic syndrome 1 9.9
114 panbronchiolitis, diffuse 9.9
115 allergic rhinitis 9.9
116 mycobacterium tuberculosis 1 9.9
117 pulmonary hypertension 9.9
118 insulin-like growth factor i 9.9
119 scleroderma, familial progressive 9.9
120 schizophrenia 9.9
121 schistosoma mansoni infection, susceptibility/ 9.9
122 proline-negative auxotroph of hamster, complementation of 9.9
123 kaposi sarcoma 9.9
124 multiple sclerosis 9.9
125 diffuse large b-cell lymphoma 9.9
126 optic neuritis 9.9
127 hemosiderosis 9.9
128 cutaneous porphyria 9.9
129 schistosomiasis 9.9
130 neuritis 9.9
131 benign mesothelioma 9.9
132 acute porphyria 9.9
133 connective tissue disease 9.9
134 b-cell lymphoma 9.9
135 neuronitis 9.9
136 pulmonary eosinophilia 9.9
137 stomatitis 9.9
138 48,xyyy 9.9
139 mycobacterium avium complex infections 9.9
140 rapidly involuting congenital hemangioma 9.9
141 burkitt lymphoma 9.9
142 pelger-huet anomaly 9.8
143 disseminated intravascular coagulation 9.8
144 capillary leak syndrome 9.8
145 lymphadenitis 9.8
146 seminoma 9.8
147 conjunctivitis 9.8
148 precursor b lymphoblastic lymphoma/leukemia 9.8
149 chronic graft versus host disease 9.8
150 systemic capillary leak syndrome 9.8
151 trisomy 1q 9.8
152 rare tumor 9.8
153 cd4/cd8 t-cell ratio 9.8
154 lymphangioleiomyomatosis 9.8
155 asthma-related traits 1 9.8
156 anxiety 9.8
157 kala-azar 1 9.8
158 aplastic anemia 9.8
159 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
160 sarcoidosis 3 9.8
161 lung cancer susceptibility 3 9.8
162 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
163 human herpesvirus 8 9.8
164 chorea, childhood-onset, with psychomotor retardation 9.8
165 deficiency anemia 9.8
166 chlamydia pneumonia 9.8
167 pulmonary alveolar microlithiasis 9.8
168 ocular motor apraxia 9.8
169 small cell cancer of the lung 9.8
170 rheumatoid arthritis 9.8
171 porphyria cutanea tarda 9.8
172 pemphigus vulgaris, familial 9.8
173 gilles de la tourette syndrome 9.8
174 lymphoma, mucosa-associated lymphoid type 9.8
175 gastroesophageal reflux 9.8
176 pfeiffer syndrome 9.8
177 intestinal schistosomiasis 9.8
178 small cell carcinoma 9.8
179 lymphoma 9.8
180 pollen allergy 9.8
181 nodal marginal zone lymphoma 9.8
182 sleeping sickness 9.8
183 bacterial infectious disease 9.8
184 japanese encephalitis 9.8
185 brucellosis 9.8
186 chlamydia 9.8
187 adult respiratory distress syndrome 9.8
188 heart disease 9.8
189 bronchial disease 9.8
190 nephrotic syndrome 9.8
191 chagas disease 9.8
192 primary biliary cirrhosis 9.8
193 blastomycosis 9.8
194 newborn respiratory distress syndrome 9.8
195 quadriplegia 9.8
196 guillain-barre syndrome 9.8
197 choreatic disease 9.8
198 uveitis 9.8
199 allergic bronchopulmonary aspergillosis 9.8
200 polyneuropathy 9.8
201 bacteriuria 9.8
202 cerebral degeneration 9.8
203 glossitis 9.8
204 pleural disease 9.8
205 histoplasmosis 9.8
206 squamous cell carcinoma 9.8
207 peritoneal mesothelioma 9.8
208 viral hepatitis 9.8
209 opportunistic mycosis 9.8
210 contact dermatitis 9.8
211 acute interstitial pneumonia 9.8
212 adenocarcinoma 9.8
213 chronic granulomatous disease 9.8
214 vaccinia 9.8
215 mixed connective tissue disease 9.8
216 shwartzman phenomenon 9.8
217 rhinitis 9.8
218 poliomyelitis 9.8
219 liver cirrhosis 9.8
220 nutritional deficiency disease 9.8
221 peripheral nervous system disease 9.8
222 hemolytic anemia 9.8
223 congenital hemolytic anemia 9.8
224 congestive heart failure 9.8
225 acquired immunodeficiency syndrome 9.8
226 lung lymphoma 9.8
227 malignant pleural mesothelioma 9.8
228 polycythemia 9.8
229 mucormycosis 9.8
230 collagen disease 9.8
231 vasculitis 9.8
232 crohn's disease 9.8
233 leishmaniasis 9.8
234 pemphigus 9.8
235 diabetic neuropathy 9.8
236 miliary tuberculosis 9.8
237 acute mountain sickness 9.8
238 exfoliative dermatitis 9.8
239 primary biliary cholangitis 9.8
240 selenium poisoning 9.8
241 stenotrophomonas maltophilia infection 9.8
242 trypanosomiasis, human east-african 9.8
243 head injury 9.8
244 tremor 9.8
245 primary pulmonary lymphoma 9.8
246 virus-associated trichodysplasia spinulosa 9.8
247 fetal lower urinary tract obstruction 9.8
248 argyria 9.8
249 respiratory bronchiolitis-interstitial lung disease syndrome 9.8
250 acute liver failure 9.8
251 adult pulmonary langerhans cell histiocytosis 9.8
252 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
253 pseudo pelger-huet anomaly 9.8

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 239, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
2
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
5
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
6
Ondansetron Approved Phase 3 99614-02-5 4595
7
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
8
Morphine Approved, Investigational Phase 3 57-27-2 5288826
9
Dalteparin Approved Phase 3 9005-49-6
10
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
13
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
14
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
15
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
16
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
17
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
18
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
19
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
20
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Mercaptopurine Approved Phase 3 50-44-2 667490
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
27
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Daunorubicin Approved Phase 3 20830-81-3 30323
30
Ichthammol Approved Phase 3 8029-68-3
31
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
32
Pegaspargase Approved, Investigational Phase 3 130167-69-0
33
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
34
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
35
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
36
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
37 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
38
Cortisone Experimental Phase 3 53-06-5 222786
39
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
40 Antiviral Agents Phase 3
41 Anti-Bacterial Agents Phase 3
42 Antibiotics, Antitubercular Phase 3
43 Topoisomerase Inhibitors Phase 3
44 Antidotes Phase 3
45
asparaginase Phase 3
46 Calcium, Dietary Phase 3
47 Anesthetics, Dissociative Phase 3
48 Neurotransmitter Agents Phase 3
49 Analgesics Phase 3
50 Cola Phase 3
51 Liver Extracts Phase 3
52 Psychotropic Drugs Phase 3
53 Tranquilizing Agents Phase 3
54 Central Nervous System Depressants Phase 3
55 Anti-Anxiety Agents Phase 3
56 Serotonin Antagonists Phase 3
57 Analgesics, Opioid Phase 3
58 Serotonin Agents Phase 3
59 Antipruritics Phase 3
60 Antipsychotic Agents Phase 3
61 Narcotics Phase 3
62 Respiratory System Agents Phase 3
63 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
64 Antitussive Agents Phase 3
65 Antiparasitic Agents Phase 3
66 Antiprotozoal Agents Phase 3
67 Heparin, Low-Molecular-Weight Phase 3
68 Excitatory Amino Acid Antagonists Phase 3
69 Excitatory Amino Acids Phase 3
70 Anesthetics, Intravenous Phase 3
71 Adjuvants, Anesthesia Phase 3
72 Anesthetics Phase 3
73 Anesthetics, General Phase 3
74 Ferric Compounds Phase 3
75 ferric gluconate Phase 3
76 Iron Supplement Phase 3
77 Liposomal amphotericin B Phase 3
78 Etoposide phosphate Phase 2, Phase 3
79 Hydrocortisone 17-butyrate 21-propionate Phase 3
80 Hydrocortisone hemisuccinate Phase 3
81 Antineoplastic Agents, Phytogenic Phase 3
82 HIV Protease Inhibitors Phase 3
83
protease inhibitors Phase 3
84 Tubulin Modulators Phase 3
85 Antimitotic Agents Phase 3
86 BB 1101 Phase 3
87
Liposomal doxorubicin Phase 3 31703
88 Micronutrients Phase 3
89 2-Aminopurine Phase 3
90 Trace Elements Phase 3
91 Vitamins Phase 3
92 Hematinics Phase 3
93 Hydrocortisone-17-butyrate Phase 3
94 Nutrients Phase 3
95
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
96
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
97
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
98
alemtuzumab Approved, Investigational Phase 2 216503-57-0
99
Voriconazole Approved, Investigational Phase 2 137234-62-9 71616
100
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
101
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
102
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
103
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
104
Allopurinol Approved Phase 1, Phase 2 315-30-0 2094
105
Acyclovir Approved Phase 1, Phase 2 59277-89-3 2022
106
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
107
Idarubicin Approved Phase 2 58957-92-9 42890
108
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
109
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616 46835353
110
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
111
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
112
rituximab Approved Phase 2 174722-31-7 10201696
113
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
114
Clofarabine Approved, Investigational Phase 1, Phase 2 123318-82-1 119182
115
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
116
Cladribine Approved, Investigational Phase 1, Phase 2 4291-63-8 20279
117
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
118
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
119
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
120
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
121
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
122
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
123
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
124 Staurosporine Experimental Phase 2 62996-74-1
125
Treosulfan Investigational Phase 2 299-75-2 9296
126 Imatinib Mesylate Phase 2 220127-57-1 123596
127 Antibodies Phase 1, Phase 2
128 Immunoglobulins Phase 1, Phase 2
129 Anti-HIV Agents Phase 2
130 Interleukin-2 Phase 2
131 Mitogens Phase 2
132 14-alpha Demethylase Inhibitors Phase 2
133 Cytochrome P-450 CYP3A Inhibitors Phase 2
134 Steroid Synthesis Inhibitors Phase 2
135 Interferon-alpha Phase 2
136 interferons Phase 2
137 Interferon alpha-2 Phase 2
138 Anti-Asthmatic Agents Phase 1, Phase 2
139
Beclomethasone Phase 1, Phase 2 4419-39-0 20469
140 Radiation-Protective Agents Phase 1, Phase 2
141 Flt3 ligand protein Phase 1, Phase 2
142
Isophosphamide mustard Phase 1, Phase 2 0
143 Ophthalmic Solutions Phase 1, Phase 2
144 Antioxidants Phase 1, Phase 2
145 Free Radical Scavengers Phase 1, Phase 2
146 Epoetin alfa Phase 2 113427-24-0
147 Sodium Channel Blockers Phase 1, Phase 2
148 Diuretics, Potassium Sparing Phase 1, Phase 2
149 Cytochrome P-450 Enzyme Inducers Phase 1, Phase 2
150 Anticonvulsants Phase 1, Phase 2
151 Interleukin-4 Phase 1, Phase 2
152 polysaccharide-K Phase 1, Phase 2
153 Protein Kinase Inhibitors Phase 2
154 Antineoplastic Agents, Immunological Phase 2
155 Adjuvants, Immunologic Phase 1, Phase 2
156 Antitubercular Agents Phase 1, Phase 2
157 2-chloro-3'-deoxyadenosine Phase 1, Phase 2
158 Vidarabine Phosphate Phase 1, Phase 2
159 Antibodies, Monoclonal Phase 2
160 Antibodies, Bispecific Phase 2
161 Thymoglobulin Phase 2
162 Histone Deacetylase Inhibitors Phase 2
163
Topotecan Approved, Investigational Phase 1 123948-87-8, 119413-54-6 60700
164
Arsenic trioxide Approved, Investigational Phase 1 1327-53-3 518740
165
Vinorelbine Approved, Investigational Phase 1 71486-22-1 60780 44424639
166
Pancrelipase Approved, Investigational Phase 1 53608-75-6
167
Fluorouracil Approved Phase 1 51-21-8 3385
168
carbamide peroxide Approved Phase 1 124-43-6
169
Methoxsalen Approved Phase 1 298-81-7 4114